AstraZeneca breast cancer medicine slows disease by over six months

AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six months in trials. Camizestrant, combined with other medicines, helped patients live longer without cancer worsening. AstraZeneca hopes this data will establish a new treatment approach. The company anticipates significant sales, though analysts offer more conservative estimates.
Tired of too many ads?
Remove Ads
New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant , in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment.Astra hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer patients.Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow.When other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion. AstraZeneca has established itself as a cancer drug powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

NDTV

13-06-2025

• NDTV

AstraZeneca Inks China AI Research Deal For Chronic Diseases

British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC Pharmaceuticals worth up to $5.3 billion to tackle chronic diseases. AstraZeneca, which has a pre-existing collaboration with CSPC, announced earlier this year plans to invest $2.5 billion in China. "This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally," said AstraZeneca executive vice president Sharon Barr. AstraZeneca aims to develop a research and development centre of up to 1,700 people in the country. CSPC will carry out the research in Shijiazhuang, using "their AI-driven, dual-engine efficient drug discovery platform", the firm said. AstraZeneca said the agreement will see CSPC receive an upfront payment of $110 million, plus up to $1.62 billion in "potential development milestone payments" and up to a further $3.6 billion in sales milestone payments, along with annual sales-based royalties. The multinational will also be able to exercise options for exclusive licences to develop and commercialise worldwide candidates identified under the deal.

Economic Times

13-06-2025

• Economic Times

AstraZeneca signs AI research deal with China's CSPC for chronic diseases

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City. "This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally," AstraZeneca executive Sharon Barr said in a statement. Friday's agreement follows AstraZeneca's announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with Immunai, and Tempus AI. AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion for reaching development milestones and $3.6 billion linked to sales-related milestones, the groups said in separate statements. They signed a licensing deal last October in which AstraZeneca agreed to pay up to $1.92 billion to CSPC to develop a candidate which would boost its cardiovascular pipeline. AstraZeneca and CSPC both have wide-ranging pipeline portfolios, including cancer treatments and those targeting cardiovascular diseases. However, about 80% of CSPC's total revenue comes from its finished drug segment, according Morningstar analysts. The Chinese group said last month it was in negotiations with third parties on new licensing and collaboration. Friday's agreement also gives AstraZeneca the rights to exercise options for exclusive licenses for candidates identified as part of the collaboration.

Time of India

12-06-2025

• Time of India

The leading risk factor for cancer isn't what you think

Vancouver: If you were to ask most people what causes cancer, the answer would probably be smoking, alcohol, the sun, hair dye or some other avoidable element. But the most important risk factor for cancer is something else: aging. That's right, the factor most associated with cancer is unavoidable - and a condition that we will all experience. Why is this important? Older adults are the fastest growing population in Canada and globally. By 2068, approximately 29 per cent of Canadians will be over age 65. With cancer being one of the most common diseases in older adults and one of the most common diseases in Canada, it means we need to think about how to provide the best cancer care for older adults. Demographic shift So how are we doing so far? The answer is: not great. This may be surprising, but we also have a great opportunity to innovate and prepare for this demographic shift in cancer care. International guidelines - including those from the American Society of Clinical Oncology - say that all older adults should have a geriatric assessment prior to making a decision about their cancer treatment. The most widely used models of geriatric assessment involve a geriatrician. Consultation with a geriatrician for an older adult allows the oncologist and older adult to engage in a conversation about cancer treatment armed with information. Things like how treatment might affect their cognition, their function, their existing illnesses (which most older adults have when they are diagnosed with cancer), and the years of remaining life. Importantly, geriatricians centre their assessment on what matters most to patients. This approach anchors any decision about cancer around the wishes of older adults and their support system. When diagnosed with cancer, older adults undergo many tests and measures of function, but the evidence supports that these are not as accurate as geriatric assessment for identifying problems that may be below the surface. Care in Canada In Canada, there are currently only a handful of specialized geriatric oncology clinics. The oldest clinic is in Montreal at the Jewish General Hospital , followed closely by the Older Adult with Cancer Clinic at Princess Margaret Cancer Centre in Toronto, led by Shabbir Alibhai , one of the authors of this story. As researchers, we are in touch with clinics in Ontario and Alberta that have told us they have geriatric oncology services under development, so we hope to see new programs soon. These clinics aren't just good for patients. In fact, a study led by Shabbir Alibhai demonstrated a cost savings of approximately $7,000 per older adult seen in these clinics. If we map this onto the number of older adults diagnosed with cancer in Canada every year, this represents a huge cost savings for our public health system. Despite this overwhelming evidence, this is still not routine care. In British Columbia, there are currently no specialized services for older adults with cancer. Over the last five years, Kristen Haase - also an author of this story - has been working with colleagues to understand whether these services are needed and how they could help older adults with cancer in B.C. This work involved conversations with more than 100 members of the cancer community. The research team spoke with older adults undergoing cancer treatment, who sometimes had to relocate for cancer treatment. Other participants included caregivers who cared for elderly family members during their cancer treatment and described numerous challenges they faced, and volunteers who ran a free transportation service - a service also mostly staffed by older adult volunteers. The research team also heard from health-care professionals: oncologists, nurses, physiotherapists and social workers. The latter group coalesced around the need for additional supports within the cancer care system so they could do their job well, and best support older adults. The results indicate that both those working in the system and those using the system want and need better support. Barriers to care So where are we now and why don't we have these services across Canada? Cost is obviously a barrier to any health-care service. But with evidence that any costs will be offset by demonstrated cost savings, this is a non-starter. Health human resources are one huge restriction. Geriatricians are in high demand and there is low supply. However, nurse-led models have also been shown to be successful. With the expanding role of nurse practitioners across Canada, this option has huge potential to innovate care, and at a lower cost. Another reason is good old inertia. Our clinical care model in oncology has remained mostly intact for over three decades. It is primarily a single physician-driven model. Although modern therapies for cancer have emerged at a breathtaking pace and have been introduced into clinical practice, it is much harder to change the model of care, particularly for strategies such as geriatric assessment that are harder to implement than a new drug or surgical/radiation technique. The last, and perhaps the most difficult to pin down of all potential reasons for the absence of specialized cancer services for older adults, is agism. Agism is discrimination based on age. It is one of the most common forms of discrimination and it is deeply embedded in many of our systems. Imagine a scenario where children diagnosed with cancer couldn't access a pediatrician. We would collectively be outraged. Yet somehow, we accept this for older adults. Due to the overwhelming number of older adults who are and will be diagnosed with cancer in the coming years, it will never be possible for all of them to receive specialized geriatric services. But there is an opportunity to innovate models of care that are targeted to those who need services the most: those who are most frail, are most likely to benefit from tailored care, and will reap the most benefit in terms of quality of life. Stratifying these programs around those who need them the most will also have the greatest financial impact. And if personal stories of improving quality of life for older adults with cancer or international guidelines don't move decision-makers, hopefully cost savings will. (The Conversation)